| scholarly article | Q13442814 |
| P50 | author | Hyunseok Kang | Q52984252 |
| Amit Mahipal | Q79225628 | ||
| Tanguy Y Seiwert | Q89776148 | ||
| P2093 | author name string | Robert Haddad | |
| Jonathan D Cheng | |||
| Bhumsuk Keam | |||
| Se-Hoon Lee | |||
| Laura Q M Chow | |||
| Hyun Cheol Chung | |||
| Jared Weiss | |||
| Makoto Tahara | |||
| Raanan Berger | |||
| Chia-Chi Lin | |||
| Marisa Dolled-Filhart | |||
| Shilpa Gupta | |||
| Kei Muro | |||
| Barbara Burtness | |||
| Ranee Mehra | |||
| Ravit Geva | |||
| Joseph Paul Eder | |||
| Kumudu Pathiraja | |||
| Amy Meister | |||
| P2860 | cites work | Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma | Q37079178 |
| Treatment of recurrent metastatic head and neck cancer: focus on cetuximab | Q37218978 | ||
| State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. | Q38211309 | ||
| Immunotherapy for head and neck squamous cell carcinoma. | Q38333662 | ||
| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | Q38849759 | ||
| Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. | Q39248696 | ||
| B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma | Q40626031 | ||
| Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma | Q41980925 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production | Q24292957 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| American Cancer Society Head and Neck Cancer Survivorship Care Guideline | Q26752802 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial | Q27853153 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas | Q35008028 | ||
| A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer | Q35169110 | ||
| PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma | Q36561681 | ||
| Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. | Q36764761 | ||
| Promising systemic immunotherapies in head and neck squamous cell carcinoma | Q36883848 | ||
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| biomarker | Q864574 | ||
| pembrolizumab | Q13896859 | ||
| head and neck squamous cell carcinoma | Q18348812 | ||
| P304 | page(s) | 3838-3845 | |
| P577 | publication date | 2016-09-30 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort | |
| P478 | volume | 34 |
| Q90287047 | A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers |
| Q41928232 | A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response? |
| Q64091981 | A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) |
| Q49821268 | A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q101038691 | A role for the immune system in advanced laryngeal cancer |
| Q48240243 | AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. |
| Q28080113 | Advances in Cancer Immunotherapy in Solid Tumors |
| Q102152216 | An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC |
| Q58095080 | An update: emerging drugs to treat squamous cell carcinomas of the head and neck |
| Q39210287 | Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? |
| Q59350023 | Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) |
| Q92671530 | Association of Posttreatment Lymphopenia and Elevated Neutrophil-to-Lymphocyte Ratio With Poor Clinical Outcomes in Patients With Human Papillomavirus-Negative Oropharyngeal Cancers |
| Q48289963 | Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. |
| Q97529382 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort |
| Q93054476 | Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation |
| Q56891609 | Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond |
| Q90226660 | Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization |
| Q52597553 | Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. |
| Q89937766 | Buparlisib-and the continued quest for the ideal cure |
| Q96437230 | CD8+CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue |
| Q49638561 | Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma |
| Q64931054 | Cancer immunotherapy: broadening the scope of targetable tumours. |
| Q47095674 | Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma |
| Q53098427 | Checkpoint immunotherapy in head and neck cancers. |
| Q50021063 | Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review |
| Q47943881 | Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q33803297 | Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. |
| Q55617875 | Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. |
| Q64983989 | Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. |
| Q41886564 | Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. |
| Q64910760 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. |
| Q59351645 | Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial |
| Q64991526 | Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. |
| Q38818008 | Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. |
| Q59813521 | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q60046462 | Current Options and Future Directions in Immune Therapy for Glioblastoma |
| Q90232439 | Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors |
| Q90413950 | Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer |
| Q39084115 | Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva |
| Q56890243 | Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors |
| Q38808580 | Current studies of immunotherapy in head and neck cancer |
| Q59352525 | Detailed analysis of adenosine A2a receptor () and CD73 (5'-nucleotidase, ecto, ) methylation and gene expression in head and neck squamous cell carcinoma patients |
| Q58795673 | Drug response to PD-1/PD-L1 blockade: based on biomarkers |
| Q91084541 | Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer |
| Q93022577 | Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center |
| Q90088012 | Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance |
| Q89326677 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 |
| Q90681595 | Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial |
| Q38779793 | Evaluation of dosing strategy for pembrolizumab for oncology indications |
| Q33650470 | Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Q92608513 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors |
| Q54269200 | Frameshift events predict anti-PD-1/L1 response in head and neck cancer. |
| Q50440650 | GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. |
| Q93197142 | Gastrointestinal cancer stem cells as targets for innovative immunotherapy |
| Q90698029 | Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors |
| Q38776454 | Genomic sequencing and precision medicine in head and neck cancers |
| Q41934319 | HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers |
| Q90134450 | HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma |
| Q92276367 | Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma |
| Q38650710 | Head and Neck Carcinoma Immunotherapy: Facts and Hopes |
| Q90664639 | Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers |
| Q46048688 | Head and neck cancer in 2016: A watershed year for improvements in treatment? |
| Q49960053 | Head and neck cancer in Hong Kong. |
| Q92531037 | Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients |
| Q33607965 | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment |
| Q64062957 | Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy |
| Q60958232 | How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies |
| Q90661296 | Hypopharyngeal carcinoma: Do you know your guidelines? |
| Q60049880 | Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma |
| Q50021106 | Immune Checkpoint Blockade: The New Frontier in Cancer Treatment |
| Q58694216 | Immune Checkpoint Inhibition in Head and Neck Cancer |
| Q92209204 | Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy |
| Q93270162 | Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma |
| Q47400647 | Immune checkpoint inhibitors: new strategies to checkmate cancer |
| Q95933555 | Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma |
| Q45936626 | Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. |
| Q45933560 | Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. |
| Q92616105 | Immunological Agents Used in Cancer Treatment |
| Q90326694 | Immunological and classical subtypes of oral premalignant lesions |
| Q64073892 | Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma |
| Q91637388 | Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer |
| Q53704789 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q38736238 | Immunotherapy for head and neck cancer: the future of treatment? |
| Q90428319 | Immunotherapy for head and neck cancer: where are we now and where are we going? |
| Q38629357 | Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. |
| Q89420575 | Immunotherapy in Head and Neck Squamous Cell Cancer |
| Q33756244 | Immunotherapy in head and neck cancer: aiming at EXTREME precision |
| Q49557927 | Immunotherapy in head and neck cancer: evidence and perspectives |
| Q38649914 | Immunotherapy: Who Is Eligible? |
| Q91424525 | Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis |
| Q47592007 | Implications of the tumor immune microenvironment for staging and therapeutics |
| Q92030460 | Importance of the immune system in head and neck cancer |
| Q58760723 | Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer |
| Q90468395 | Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma |
| Q33884361 | Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives |
| Q89965765 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment |
| Q39015086 | Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. |
| Q92987477 | Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma |
| Q57216378 | Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma |
| Q94545882 | Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma |
| Q53682256 | Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. |
| Q50116331 | Leveraging Genomics for Head and Neck Cancer Treatment |
| Q90774449 | Making the right calls in precision oncology |
| Q39272385 | Management of elderly patients with locoregionally confined head and neck cancer |
| Q55314300 | Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. |
| Q39190066 | Mechanistic and pharmacologic insights on immune checkpoint inhibitors |
| Q37622998 | Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report |
| Q92586148 | Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab |
| Q38671420 | Multiparametric immune profiling in HPV- oral squamous cell cancer |
| Q50336126 | New developments in the management of head and neck cancer – impact of pembrolizumab |
| Q38635035 | Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck |
| Q57492388 | On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies |
| Q38614781 | Optimizing tumor immune response through combination of radiation and immunotherapy. |
| Q90353785 | Overexpression of TRMT12 may independently predict poor overall survival in patients with head and neck squamous cell carcinoma |
| Q38649562 | PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence |
| Q60960096 | PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection |
| Q50054711 | PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas |
| Q52723008 | PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. |
| Q64882611 | PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. |
| Q40208391 | PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients |
| Q37623044 | PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma |
| Q64914214 | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. |
| Q93077961 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study |
| Q39193035 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. |
| Q64073848 | Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients? |
| Q49925686 | Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study |
| Q49036770 | Pembrolizumab for the treatment of bladder cancer |
| Q55253213 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. |
| Q42023824 | Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm |
| Q90224620 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study |
| Q60908672 | Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma |
| Q90418185 | Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study |
| Q88380021 | Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma |
| Q92060396 | Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date |
| Q58579220 | Predicting 90-Day Mortality in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma after Curative Surgery |
| Q95591987 | Preface: More than two decades of modern tumor immunology |
| Q89450684 | Preface: More than two decades of modern tumor immunology |
| Q91284516 | Preface: More than two decades of modern tumor immunology |
| Q96612904 | Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis |
| Q41633683 | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
| Q92197846 | Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment |
| Q53097632 | Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. |
| Q64280005 | Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile |
| Q64277679 | Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients |
| Q39013253 | Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma |
| Q48197242 | Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. |
| Q91650557 | Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies |
| Q59805349 | Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers |
| Q87593529 | Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma |
| Q38654727 | Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions |
| Q54723806 | Putting T cells to work-outsourcing neoantigen detection in head and neck cancers? |
| Q92306377 | Radioimmunotherapy for the treatment of head and neck cancer |
| Q49968491 | Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review |
| Q52602002 | Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q64091122 | Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada |
| Q90154661 | Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy |
| Q93147363 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression |
| Q88442150 | Reirradiation of head and neck cancer using modern highly conformal techniques |
| Q98466646 | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors |
| Q43234029 | Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. |
| Q99408581 | Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma |
| Q58573986 | Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not |
| Q47437627 | SEOM clinical guidelines for the treatment of head and neck cancer (2017). |
| Q92263399 | SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q58082830 | Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial |
| Q47169813 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. |
| Q64066298 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer |
| Q88654117 | Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study |
| Q52655048 | Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. |
| Q91015143 | Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial |
| Q92632643 | Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review |
| Q52651819 | Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. |
| Q52617485 | Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. |
| Q55457406 | Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer. |
| Q91717183 | Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 |
| Q55644910 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. |
| Q64927095 | Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go? |
| Q38851114 | Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies |
| Q54217605 | Targeting Head and Neck Cancer by Vaccination. |
| Q90166671 | Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer |
| Q46129475 | Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape |
| Q90290730 | The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer |
| Q93189796 | The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions |
| Q91895909 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) |
| Q64986397 | The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer. |
| Q92691192 | The changing therapeutic landscape of head and neck cancer |
| Q58561576 | The clinical role of the TME in solid cancer |
| Q97525200 | The impact of the COVID-19 pandemic on head and neck cancer patients |
| Q64066287 | The neoepitope landscape of breast cancer: implications for immunotherapy |
| Q90435536 | Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation |
| Q57816910 | Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
| Q47393365 | Trial watch: Immune checkpoint blockers for cancer therapy |
| Q52681592 | Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q97432032 | Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells |
| Q100391110 | Tumor microenvironment characterization in head and neck squamous carcinoma reveals distinct genomic alterations and clinical outcomes |
| Q50545401 | Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. |
| Q92037447 | Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma |
| Q39194722 | Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response |
| Q90199539 | Who is who in oral cancer? |
| Q99632545 | [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma] |
| Q64889726 | mTOR Signalling in Head and Neck Cancer: Heads Up. |
| Q42363764 | mTOR co-targeting strategies for head and neck cancer therapy |
| Q90577000 | miR-23a-3p/SIX1 regulates glucose uptake and proliferation through GLUT3 in head and neck squamous cell carcinomas |
Search more.